Watch PASG. Know when insiders buy.
One email the day a filing lands. Free.
PASG
Passage BIO, Inc.
3.59
−0.01 −0.28%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $11.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$36.1MNET CASH —52W 3.50 – 19.85SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$8.3M | −$7.8M | — | -2.44 | −$9.2M | — | — | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$8.2M | −$7.6M | — | -2.36 | −$13M | — | — | May 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$13.8M | −$13M | — | -4.09 | −$6.5M | — | — | Mar 3 |
| Q3 2025 · Sep 30 | — | — | — | −$8.7M | −$7.7M | — | -2.44 | −$4.9M | — | — | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$10.3M | −$9.4M | — | -2.96 | −$6.3M | — | — | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$16.5M | −$15.4M | — | -4.87 | −$13.8M | — | — | May 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$14.3M | −$12.7M | — | -4.00 | −$8.4M | — | — | Mar 3 |
| Q3 2024 · Sep 30 | — | — | — | −$20.7M | −$19.3M | — | -6.15 | −$7.4M | — | — | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$17.4M | −$16M | — | -5.09 | −$13.1M | — | — | Aug 12 |
| Q1 2024 · Mar 31 | — | — | — | −$18.1M | −$16.7M | — | -0.30 | −$18.9M | — | — | May 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$18.4M | −$16.8M | — | -0.30 | −$19.5M | — | — | Mar 4 |
| Q3 2023 · Sep 30 | — | — | — | −$28.7M | −$27.1M | — | -0.49 | −$19.2M | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$49.3M | −$45.5M | — | -14.35 | −$31.5M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$70.4M | −$64.8M | — | -21.04 | −$48M | $34K | −$48M | — | — |
| FY2023 · to Dec 31 | — | — | −$108.4M | −$102.1M | — | -1.86 | −$78.3M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$138.4M | −$136.1M | — | -2.50 | −$118.2M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$185.7M | −$185.4M | — | -3.48 | −$126.9M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$112.9M | −$112.2M | — | -2.91 | −$80.5M | — | — | — | — |
Every number comes from Passage BIO, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.